Repurposing anticancer drugs for the management of COVID-19

Detalhes bibliográficos
Autor(a) principal: El Bairi, Khalid
Data de Publicação: 2020
Outros Autores: Trapani, Dario, Petrillo, Angelica, Le Page, Cécile, Zbakh, Hanaa, Daniele, Bruno, Belbaraka, Rhizlane, Curigliano, Giuseppe, Afqir, Said
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.1/14948
Resumo: Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing.
id RCAP_f5e6201fade4907928b24a2c532b5c4e
oai_identifier_str oai:sapientia.ualg.pt:10400.1/14948
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Repurposing anticancer drugs for the management of COVID-19Antineoplastic agentsAntiviral agentsCOVID-19HumansPandemicsSARS-CoV-2Drug repositioningSince its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing.ElsevierSapientiaEl Bairi, KhalidTrapani, DarioPetrillo, AngelicaLe Page, CécileZbakh, HanaaDaniele, BrunoBelbaraka, RhizlaneCurigliano, GiuseppeAfqir, Said2021-01-11T18:33:48Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/14948eng0959-804910.1016/j.ejca.2020.09.014info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:27:19Zoai:sapientia.ualg.pt:10400.1/14948Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:05:53.507456Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Repurposing anticancer drugs for the management of COVID-19
title Repurposing anticancer drugs for the management of COVID-19
spellingShingle Repurposing anticancer drugs for the management of COVID-19
El Bairi, Khalid
Antineoplastic agents
Antiviral agents
COVID-19
Humans
Pandemics
SARS-CoV-2
Drug repositioning
title_short Repurposing anticancer drugs for the management of COVID-19
title_full Repurposing anticancer drugs for the management of COVID-19
title_fullStr Repurposing anticancer drugs for the management of COVID-19
title_full_unstemmed Repurposing anticancer drugs for the management of COVID-19
title_sort Repurposing anticancer drugs for the management of COVID-19
author El Bairi, Khalid
author_facet El Bairi, Khalid
Trapani, Dario
Petrillo, Angelica
Le Page, Cécile
Zbakh, Hanaa
Daniele, Bruno
Belbaraka, Rhizlane
Curigliano, Giuseppe
Afqir, Said
author_role author
author2 Trapani, Dario
Petrillo, Angelica
Le Page, Cécile
Zbakh, Hanaa
Daniele, Bruno
Belbaraka, Rhizlane
Curigliano, Giuseppe
Afqir, Said
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv El Bairi, Khalid
Trapani, Dario
Petrillo, Angelica
Le Page, Cécile
Zbakh, Hanaa
Daniele, Bruno
Belbaraka, Rhizlane
Curigliano, Giuseppe
Afqir, Said
dc.subject.por.fl_str_mv Antineoplastic agents
Antiviral agents
COVID-19
Humans
Pandemics
SARS-CoV-2
Drug repositioning
topic Antineoplastic agents
Antiviral agents
COVID-19
Humans
Pandemics
SARS-CoV-2
Drug repositioning
description Since its outbreak in the last December, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has rapidly spread worldwide at a pandemic proportion and thus is regarded as a global public health emergency. The existing therapeutic options for COVID-19 beyond the intensive supportive care are limited, with an undefined or modest efficacy reported so far. Drug repurposing represents an enthusiastic mechanism to use approved drugs outside the scope of their original indication and accelerate the discovery of new therapeutic options. With the emergence of COVID-19, drug repurposing has been largely applied for early clinical testing. In this review, we discuss some repurposed anticancer drugs for the treatment of COVID-19, which are under investigation in clinical trials or proposed for the clinical testing.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
2021-01-11T18:33:48Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/14948
url http://hdl.handle.net/10400.1/14948
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0959-8049
10.1016/j.ejca.2020.09.014
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133298926026752

Registros relacionados